Authors: Tamminga, WJ Wemer, J Oosterhuis, B Wieling, J Touw, DJ de Zeeuw, RA de Leij, LFMH Jonkman, JHG

Citation: Wj. Tamminga et al., Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events, BR J CL PH, 51(5), 2001, pp. 471-474

Authors: Tamminga, WJ Wemer, J Oosterhuis, B Brakenhoff, JPG Gerrits, MGF de Zeeuw, RA de Leij, LFMH Jonkman, JHG

Citation: Wj. Tamminga et al., An optimized methodology for combined phenotyping and genotyping on CYP2D6and CYP2C19, EUR J CL PH, 57(2), 2001, pp. 143-146

Authors: Wieling, J Tamminga, WJ Sakiman, EP Oosterhuis, B Wemer, J Jonkman, JHG

Citation: J. Wieling et al., Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening, THER DRUG M, 22(4), 2000, pp. 486-496

Authors: Le Liboux, A Cachia, JP Kirkesseli, S Gautier, JY Guimart, C Montay, G Peeters, PAM Groen, E Jonkman, JHG Wemer, J

Citation: A. Le Liboux et al., A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers, J CLIN PHAR, 39(5), 1999, pp. 480-486

Authors: Tamminga, WJ Wemer, J Oosterhuis, B Wieling, J Wilffert, B de Leij, LFMH de Zeeuw, RA Jonkman, JHG

Citation: Wj. Tamminga et al., CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences, EUR J CL PH, 55(3), 1999, pp. 177-184

Authors: Young, MMR Squassante, L Wemer, J van Merle, SP Dogterom, P Jonkman, JHG

Citation: Mmr. Young et al., Troglitazone has no effect on red cell mass or other erythropoietic parameters, EUR J CL PH, 55(2), 1999, pp. 101-104